OpenAI Buys Orchestra Bio to Build Drug Development Agents

OpenAI has acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development, OpenAI announced on October 20, 2026. OpenAI said it is bringing Orchestra’s team and technology together with Rosalind, its AI models and tools for life sciences research, with the stated goal of helping scientists make discoveries and manage the work needed to turn them into treatments that reach patients sooner.

Orchestra Bio Inc. confirmed the deal on its own website, saying it is joining OpenAI to continue its mission at an even greater scale, and thanked its customers, investors, and supporters. The company said it started four years ago to help biotech and pharma teams advance their drug development programs.

How the Orchestra Platform Works

Developing a new medicine takes roughly 10 to 15 years on average from target discovery to regulatory approval in the United States, OpenAI stated, and beyond the science, teams must orchestrate programs across internal departments and external partners, often relying on disconnected systems. Orchestra Bio described the challenge in similar terms, stating that developing medicines spans thousands of decisions and dependencies across discovery, preclinical, manufacturing, and clinical work. Both companies said AI has reached an inflection point at which people and agents can take on specialized tasks and complex workflows together.

OpenAI described Orchestra Bio as a platform where people and AI agents work together to advance drug programs. Scientists and program leaders delegate the monitoring and tracking of studies and campaigns to agents, freeing time to guide the work, make decisions, and address issues before they cause delays. Because a problem in one part of a drug program can affect many others, OpenAI gave the example of a failed manufacturing batch delaying the start of a clinical trial; Orchestra’s agents, it said, identify which activities and timelines are affected, gather the relevant information, and compare ways to respond, so that scientists and program leaders can use that analysis to decide what to do next. In Orchestra Bio’s own words: “Agents can handle planning, orchestration, and analysis, while scientists and program leaders focus on the decisions that require their expertise.”

OpenAI said Orchestra brings a team with experience across biotech, software, and AI, along with a platform built to coordinate drug development. OpenAI said that together the companies aim to build agents that help teams connect scientific findings with the studies, decisions, and next steps needed to advance a potential medicine.

Rosalind Products, Partnerships, and Access Programs

Rosalind is OpenAI’s life sciences brand, pairing the GPT-Rosalind model with Rosalind Workbench, an orchestrated workspace for scientific research. According to OpenAI’s Rosalind page, GPT-Rosalind is a purpose-built model for life sciences research, with expanded access for eligible organizations pursuing specialized life sciences research. The page lists an Explore mode for general scientific questions and a Research mode for more complex biological questions, in-depth analysis, and advanced scientific research workflows, with Research mode requiring an access application. Users can also run GPT-Rosalind in Codex to connect scientific tools, data, and evidence into research workflows that teams can review, share, and reuse, or build with the GPT-Rosalind API, which OpenAI says is subject to eligibility review and organizational approval. Rosalind Workbench is in research preview, the page states.

The page reports benchmark results stated as increases in performance per token: 53.7% on Genebench, 18.0% on Medchem Bench, 19.6% on Labworkbench, and 4.42% on LifeSci Bench. Listed capabilities include prioritizing targets, engineering proteins, synthesizing evidence, analyzing data, and saving workflows that teams can inspect, share, and reuse. The page also describes a guided NGS workflow in Workbench in which researchers bring in sequencing files and sample details, check inputs, approve the analysis plan, follow the run, and inspect quality-control metrics and saved outputs before choosing the next biological question.

OpenAI said its partnership with Novo Nordisk aims to translate the drugmaker’s scale and scientific expertise into faster R&D and commercial execution while maintaining strong governance. On the Rosalind page, Novo Nordisk CEO and President Mike Doustdar said the partnership “will help translate this scale into faster R&D and commercial execution, while maintaining the governance our patients and society expect.” OpenAI also said that at Moderna, AI is helping teams translate insights from complex data into experimental workflows, with the potential to accelerate R&D.

The Rosalind page lists several access routes: the Rosalind Academic Plan, which offers eligible labs sponsored access to GPT-Rosalind and tools for life sciences discovery; enterprise access with governance review and enterprise-grade deployment controls; and reviewed access for government and public-health teams for legitimate research, preparedness, and resilience work with clear public-benefit boundaries. A separate Rosalind Biodefense program supports trusted developers and public-health teams building defensive applications with GPT-Rosalind, with focus areas including early detection, preparedness, diagnostics, response, and medical countermeasures.

OpenAI said its vision is for AI to help scientists across the full process of discovering and developing new medicines: exploring ideas, designing experiments, interpreting results, and coordinating the work needed to advance promising treatments. Bringing Orchestra Bio together with Rosalind, the company said, is a step toward that vision.